Article Per Year (5 Year)
p-Index From 2020 - 2025
0.983
P-Index
This Author published in this journals
All Journal Jurnal Sintesis: Penelitian Sains, Terapan dan Analisisnya Journal for Quality in Public Health Jurnal Pharma Bhakta Strada Journal of Pharmacy Jurnal Kajian dan Inovasi Ilmu (JKII)
Yogi Bhakti Marhenta
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Humanities Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Education Environmental Science Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Materials Science & Nanotechnology Mathematics Medicine & Pharmacology Physics Public Health Social Sciences Other

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search

 1 
ANALISIS BIAYA RIIL TERHADAP TARIF INA-CBG’S PADA PASIEN BPJS PNEUMONIA ANAK DI RUMAH SAKIT X DI KOTA MADIUN TAHUN 2019-2021: ANALISIS BIAYA RIIL TERHADAP TARIF INA-CBG’S PADA PASIEN BPJS PNEUMONIA Yogi Bhakti Marhenta; Wika Admaja; Krisogonus Ephrino Seran; Alfira Nurfaini Effendy
Jurnal Sintesis: Penelitian Sains, Terapan dan Analisisnya Vol 3 No 2 (2022): Desember 2022
Publisher : Fakultas Sains, Teknologi, dan Analsisi Institut ilmu Kesehatan Bhakti Wiyata

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56399/jst.v3i2.61

Abstract

Pneumonia merupakan salah satu penyebab kematian utama pada anak balita di dunia, selaras dengan pernyataan badan kesehatan dunia (2013) yang menyatakan bahwa kejadian kematian akibat pneumonia pada anak masih menjadi salah satu masalah utama, khususnya di negara berkembang dan dijuluki ”the forgotten killer of children”. Terapi pneumonia memerlukan biaya yang cukup besar. Tingginya biaya pengobatan membuat pemerintah melahirkan solusi dengan menerapkan sistem Jaminan Kesehatan Nasional (JKN) untuk meringankan beban ekonomi masyarakat. Penelitian ini bertujuan untuk melakukan komparasi tarif klaim INA-CBGs dengan tarif riil yang dikeluarkan oleh rumah sakit. Metode penelitian menggunakan deskriptif analitik dengan pendekatan cross sectional. Populasi dalam penelitian ini ialah data rekam medis dan data administrasi kuangan pasien pneumonia anak di Sakit X Kota Madiun dari 2019-2021. Sampel yang digunakan ialah berkas rekam medis pasien yang memenuhi kriteria inklusi. Pengambilan sampel menggunakan metode purposive sampling. Ditemukan perbedaan yang signifikan antar rata-rata total biaya medis langsung pasien pneumonia anak rawat inap kategori ringan (J-4-16-I) pada kelas perawatan III dengan tarif INA-CBG’s di Rumah Sakit X Kota Madiun (p<0,05). Besar selisih yang diperoleh pada perbandingan tarif INA-CBG’s pada rata-rata total biaya riil pasien pneumonia anak kategori ringan pada kelas perawatan III sebesar Rp. -1.293.583.
ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN OMEPRAZOLE DAN RANITIDIN PADA PASIEN GASTRITIS RAWAT INAP DI RS X KABUPATEN KEDIRI Wika Admaja; Yogi Bhakti Marhenta
JURNAL PHARMA BHAKTA Vol 3 No 1 (2023): Mei 2023
Publisher : FAKULTAS FARMASI, INSTITUT ILMU KESEHATAN BHAKTI WIYATA

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Keluhan penyakit gastritis merupakan penyakit saluran cerna yang sering dijumpai, Indonesia sendiri menunjukkan persentase kasus grastritis yang cukup tinggi yakni 40,8% (WHO, 2010). Gastritis merupakan peradangan mukosa lambung yang disebabkan karena pola makan tidak teratur, stress, dan adanya infeksi Helicobacter pylori . Terapi pengobatan gastritis sering menggunakan obat golongan Proton Pump Inhibitor (PPI) atau Histamin-2-Reseptor Antagonis (H2RA). Penelitian ini bertujuan untuk mengetahui terapi yang lebih cost-efektif pada pasien dengan diagnosa gastritis rawat inap antara omeprazole dan ranitidin di RSUD Kabupaten Kediri. Metode Dalam Penelitian ini menggunakan desain cross sectional dan pengambilan data dilakukan secara retrospektif. Sampel penelitian sebanyak 33 pasien yang terdiri dari 17 pasien mendapatkan terapi omeprazole dan 16 pasien mendapatkan terapi ranitidin. Data diidentifikasi menggunakan analisis efektivitas biaya perhitungan ACER dan ICER dengan outcome terapi lenght of stay. Hasil penelitian menunjukkan omeprazole memiliki biaya lebih rendah yakni Rp. 1.490.860/pasien dan efektivitas lama perawatan lebih singkat yakni 3,5 hari, dibandingkan dengan ranitidin Rp.1.568.806/pasien dan efekvitivas 4,2 hari, dengan nilai ACER Rp. 425.960 dan ICER sebesar Rp.137.065,71, sehingga terapi omeprazole lebih cost-effective dalam pengobatan gastritis..
Cost-Effectiveness Analysis Of Ceftriaxone-Gentamicin And Ampicillin-Gentamicin In Pediatric Pneumonia At Hospital X Madiun Wika, Wika Admaja; Shania Crhisnatasha Putri; Anggi Restyana; Yogi Bhakti Marhenta
Journal for Quality in Public Health Vol. 7 No. 1 (2023): November
Publisher : Master of Public Health Program Institut Ilmu Kesehatan STRADA Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30994/jqph.v7i1.465

Abstract

Pneumonia is an infectious disease caused by bacteria characterized by fever, chills, coughing up phlegm, and breathing difficulty. Generally pneumonia is caused by an infection of Streptococcus pneumoniae bacteria. Antibiotics is a therapy used in pediatric pneumonia patients at hospitals X. in Madiun. This study aims to determine a more cost-effective antibiotics therapy combination between ceftriaxone-Gentamicin and Ampicillin-Gentamicin in pediatric pneumonia patients at Hospital X in Madiun in 2019-2021. This study used a cross sectional design and data collection was carried out retrospectively. There were 39 patients as samples who were pediatric patients aged ≤ 12 years who were adjusted to the inclusion criteria. The datawere identified using decision trees and analyzed cost-effectiveness with ACER and ICER calculations. The ACER value of Ceftriaxone-Gentamicin antibiotic therapy is IDR 6,047,334.23, which is lower than Ampicillin-Gentamicin therapy whch is of IDR 9,730,746.21, thus showing that Seftriaxone-Gentamicin is more cost-effective than Ampicillin-Gentamicin. The ICER calculation has negative result of Idr 500,953.74 so it shows that the Ceftriaxone-Gentamicin combination antibiotic is more cost-effective.
Rationality of Use of Antibiotic at North Region City Primary Health Care Centre in Kediri City Hanie Kusuma Wardani; Krisogonus Ephrino Seran; Yogi Bhakti Marhenta; Febriarmayenri
Strada Journal of Pharmacy Vol. 4 No. 2 (2022): October
Publisher : Universitas STRADA Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30994/sjp.v4i2.68

Abstract

The implementation of health services by ensuring safety, effectiveness, and affordable costs for people who receive treatment is one of the efforts carried out by the Rational Drug Use program. It is said that the use of drugs is rational if the patient gets treatment according to clinical needs, the dose is as needed, the drug can be used for a sufficient period of time and at an affordable cost. This study aims to determine the rationality of the use of antibiotic drugs at North Region City Primary Health Care Centre in Kediri City with the indicators of Right Indication, Right Patient, Right Drug, Right Dosage, and Beware of Drug Side Effects. This study is a descriptive study with retrospective data collection by looking at prescriptions and medical records of patients using antibiotics and supported by open interviews with pharmacists. Based on the results of the study showed that the use of antibiotics in 273 samples obtained Penicillin class antibiotics was 46.89%, Other Antibiotics of 26.01%, Antituberculosis of 8.42%, Quinolones at 11.72%, Aminoglycosides of 5.13%, Tetracyclines of 1.10%, and Macrolides of 0.73%. The percentage of rationality for the use of antibiotic drugs which includes indicators of Right Indication, Right Patient, Right Drug, Right Dosage, and Alert for Drug Side Effects is 96%.
Chemical Structure Profile and Computational Descriptors of Fenbufen Butanamine by PubChem Yuneka Saristiana; Fendy Prasetyawan; Ratna Mildawati; Yogi Bhakti Marhenta; Eka Hayati Rhomah; Mujtahid Bin Abd Kadir
Jurnal Kajian dan Inovasi Ilmu (JKII) Vol. 1 No. 2 (2025): November
Publisher : Marasofi International Media and Publishing (MIMP)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.64123/jkii.v1.i2.2

Abstract

Fenbufen Butanamine is a structural derivative of the non-steroidal anti-inflammatory drug (NSAID) Fenbufen, characterized by the addition of a butanamine group to its core structure. This modification is intended to improve the pharmacokinetic and pharmacodynamic properties of the parent compound, potentially enhancing its therapeutic efficacy. In this study, we conducted a detailed computational analysis of Fenbufen Butanamine’s chemical structure and molecular descriptors using data retrieved from the PubChem database. The chemical identity was confirmed by its IUPAC name, InChI, InChIKey, and SMILES notation, which provide precise molecular characterization essential for database referencing and further computational modeling. Key computational descriptors, such as molecular weight, logP, topological polar surface area (TPSA), and the count of hydrogen bond donors and acceptors, were analyzed to assess drug-likeness and predict pharmacokinetic behavior. Our findings indicate that Fenbufen Butanamine possesses a biphenyl core that contributes to hydrophobic interactions, while the butanamine side chain introduces hydrophilic properties. This amphiphilic nature is likely to influence the compound’s solubility, membrane permeability, and binding affinity to biological targets. The computed descriptors suggest favorable properties for oral bioavailability and potential interactions within biological systems. These results serve as a foundational step for in silico drug design and optimization of Fenbufen derivatives. Further experimental and pharmacological studies are warranted to validate these computational predictions and explore the therapeutic potential of Fenbufen Butanamine. 
Co-Authors Alfira Nurfaini Effendy Eka Hayati Rhomah Febriarmayenri Fendy Prasetyawan Hanie Kusuma Wardani Krisogonus Ephrino Seran Krisogonus Ephrino Seran Mujtahid Bin Abd Kadir Ratna Mildawati Restyana, Anggi Shania Crhisnatasha Putri Wika Admaja Wika Admaja Wika, Wika Admaja Yuneka Saristiana